Angiogenesis in non-small cell lung cancer: The prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood

Down-regulation of ALKBH2 increases cisplatin sensitivity in H1299 lung cancer cells

“…Our results indicate that down-regulation of ALKBH2 in cDDPtreated H1299 cells alters the expression of basic fibroblast growth factor (bFGF), platelet-derived growth factor (PDGFA, PDGFB) and Bcl-2. bFGF, an angiogenic cytokine produced by tumor cells, affects vessel formation, tumor growth, invasion and metastasis, and down-regulated bFGF may inhibit tumor growth [23] . Cell-surface receptor tyrosine kinases play pivotal roles in different diseases, ranging from cancer to vascular disorders, so disruption of PDGF signaling pathways could inhibit tumor stromogenesis [24] .…”

Serum angiopoietin-1 as a prognostic marker in resected early stage lung cancer

“…Many studies have evaluated the prognostic significance of serum VEGF in lung cancer, and most have shown positive results, but not consistently [8]. Serum VEGF has rarely been evaluated specifically in resected early stage lung cancer.…”

“…Studies of various genetic, pathologic, and clinical markers to identify the group at high risk for postoperative recurrence have produced variable results [2][3][4][5]. Angiogenesis, which is an important process in tumorigenesis, has also been evaluated for this purpose, with promising results [6][7][8].…”

Anti‐Metastatic and Anti‐Angiogenic Activities of Core–Shell SiO2@LDH Loaded with Etoposide in Non‐Small Cell Lung Cancer

“…Angiogenesis is a cascade of procedures emanating from microvascular endothelial cells. Cancer cells can escape from a tumor site and enter the blood circulation system via these new blood vessels or through the lymphatic system 35. Once arrest the new site, the continuous growth of the cancer cells must be sustained by the new vessels, thus, a micrometastasis may continue to form a macroscopic tumor 36, 37, 38, 39.…”